APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Orexin Receptor Type 2

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Orexin Receptor Type 2 Market Outlook and Growth Opportunities 2026

Report ID 174020400419 December 2025193 pages

Choose your research edition.

Industry ResearchOrexin Receptor Type 2 Industry Research Report 2026115 pages · $2,950 USDIndustry Growth & TrendsGlobal Orexin Receptor Type 2 Industry Growth and Trends Forecast to 203285 pages · $3,450 USDMarket StructureGlobal Orexin Receptor Type 2 Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032181 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Orexin Receptor Type 2 Market Outlook and Growth Opportunities 2026193 pages · $4,250 USDMarket Analysis & ForecastGlobal Orexin Receptor Type 2 Market Analysis and Forecast 2026-2032193 pages · $4,950 USD

Market perspective

The global Orexin Receptor Type 2 market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Orexin Receptor Type 2 is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Orexin Receptor Type 2 is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Orexin Receptor Type 2 is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Orexin Receptor Type 2 market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Orexin Receptor Type 2 market include Yangtze River Pharmaceutical Group, Eisai Co Ltd, Johnson & Johnson, Merck & Co Inc, OptiNose US Inc, Idorsia Ltd, Heptares Therapeutics Ltd, Evotec AG and Actelion Pharmaceuticals Ltd, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global Orexin Receptor Type 2 market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Orexin Receptor Type 2 and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Orexin Receptor Type 2 revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Orexin Receptor Type 2 market.

Orexin Receptor Type 2 Segment by Company

Yangtze River Pharmaceutical Group

Eisai Co Ltd

Johnson & Johnson

Merck & Co Inc

OptiNose US Inc

Idorsia Ltd

Heptares Therapeutics Ltd

Evotec AG

Actelion Pharmaceuticals Ltd

Orexin Receptor Type 2 Segment by Type

HTL-6641

MK-8133

OPN-021

YNT-185

Lemborexant

Others

Orexin Receptor Type 2 Segment by Application

Major Depressive Disorder

Sleep Disorders

Narcolepsy

Insomnia

Orexin Receptor Type 2 Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global Orexin Receptor Type 2 status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Orexin Receptor Type 2 key companies, revenue, market share, and recent developments.

3. To split the Orexin Receptor Type 2 breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Orexin Receptor Type 2 market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Orexin Receptor Type 2 significant trends, drivers, influence factors in global and regions.

6. To analyze Orexin Receptor Type 2 competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Orexin Receptor Type 2 market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Orexin Receptor Type 2 and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Orexin Receptor Type 2.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Orexin Receptor Type 2 industry.

Chapter 3: Detailed analysis of Orexin Receptor Type 2 company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Orexin Receptor Type 2 in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Orexin Receptor Type 2 in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Orexin Receptor Type 2 Industry Trends Table 2. Orexin Receptor Type 2 Industry Drivers Table 3. Orexin Receptor Type 2 Industry Opportunities and Challenges Table 4. Orexin Receptor Type 2 Industry Restraints Table 5. Global Orexin Receptor Type 2 Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Orexin Receptor Type 2 Revenue Share by Company (2021-2026) Table 7. Global Orexin Receptor Type 2 Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Orexin Receptor Type 2 Key Company Manufacturing Base & Headquarters Table 9. Global Orexin Receptor Type 2 Company, Product Type & Application Table 10. Global Orexin Receptor Type 2 Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Orexin Receptor Type 2 by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of HTL-6641 Table 15. Significant Companies of MK-8133 Table 16. Significant Companies of OPN-021 Table 17. Significant Companies of YNT-185 Table 18. Significant Companies of Lemborexant Table 19. Significant Companies of Others Table 20. Global Orexin Receptor Type 2 Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 21. Global Orexin Receptor Type 2 Sales Value by Type (2021-2026) & (US$ Million) Table 22. Global Orexin Receptor Type 2 Sales Value by Type (2027-2032) & (US$ Million) Table 23. Global Orexin Receptor Type 2 Sales Value Share by Type (2021-2026) Table 24. Global Orexin Receptor Type 2 Sales Value Share by Type (2027-2032) Table 25. Significant Companies of Major Depressive Disorder Table 26. Significant Companies of Sleep Disorders Table 27. Significant Companies of Narcolepsy Table 28. Significant Companies of Insomnia Table 29. Global Orexin Receptor Type 2 Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 30. Global Orexin Receptor Type 2 Sales Value by Application (2021-2026) & (US$ Million) Table 31. Global Orexin Receptor Type 2 Sales Value by Application (2027-2032) & (US$ Million) Table 32. Global Orexin Receptor Type 2 Sales Value Share by Application (2021-2026) Table 33. Global Orexin Receptor Type 2 Sales Value Share by Application (2027-2032) Table 34. Global Orexin Receptor Type 2 Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 35. Global Orexin Receptor Type 2 Sales Value by Region (2021-2026) & (US$ Million) Table 36. Global Orexin Receptor Type 2 Sales Value Share by Region (2021-2026) Table 37. Global Orexin Receptor Type 2 Sales Value by Region (2027-2032) & (US$ Million) Table 38. Global Orexin Receptor Type 2 Sales Value Share by Region (2027-2032) Table 39. Global Orexin Receptor Type 2 Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 40. Global Orexin Receptor Type 2 Sales Value by Country (2021-2026) & (US$ Million) Table 41. Global Orexin Receptor Type 2 Sales Value Market Share by Country (2021-2026) Table 42. Global Orexin Receptor Type 2 Sales Value by Country (2027-2032) & (US$ Million) Table 43. Global Orexin Receptor Type 2 Sales Value Market Share by Country (2027-2032) Table 44. Yangtze River Pharmaceutical Group Company Information Table 45. Yangtze River Pharmaceutical Group Business Overview Table 46. Yangtze River Pharmaceutical Group Orexin Receptor Type 2 Revenue (US$ Million) and Gross Margin (2021-2026) Table 47. Yangtze River Pharmaceutical Group Orexin Receptor Type 2 Product Portfolio Table 48. Yangtze River Pharmaceutical Group Recent Development Table 49. Eisai Co Ltd Company Information Table 50. Eisai Co Ltd Business Overview Table 51. Eisai Co Ltd Orexin Receptor Type 2 Revenue (US$ Million) and Gross Margin (2021-2026) Table 52. Eisai Co Ltd Orexin Receptor Type 2 Product Portfolio Table 53. Eisai Co Ltd Recent Development Table 54. Johnson & Johnson Company Information Table 55. Johnson & Johnson Business Overview Table 56. Johnson & Johnson Orexin Receptor Type 2 Revenue (US$ Million) and Gross Margin (2021-2026) Table 57. Johnson & Johnson Orexin Receptor Type 2 Product Portfolio Table 58. Johnson & Johnson Recent Development Table 59. Merck & Co Inc Company Information Table 60. Merck & Co Inc Business Overview Table 61. Merck & Co Inc Orexin Receptor Type 2 Revenue (US$ Million) and Gross Margin (2021-2026) Table 62. Merck & Co Inc Orexin Receptor Type 2 Product Portfolio Table 63. Merck & Co Inc Recent Development Table 64. OptiNose US Inc Company Information Table 65. OptiNose US Inc Business Overview Table 66. OptiNose US Inc Orexin Receptor Type 2 Revenue (US$ Million) and Gross Margin (2021-2026) Table 67. OptiNose US Inc Orexin Receptor Type 2 Product Portfolio Table 68. OptiNose US Inc Recent Development Table 69. Idorsia Ltd Company Information Table 70. Idorsia Ltd Business Overview Table 71. Idorsia Ltd Orexin Receptor Type 2 Revenue (US$ Million) and Gross Margin (2021-2026) Table 72. Idorsia Ltd Orexin Receptor Type 2 Product Portfolio Table 73. Idorsia Ltd Recent Development Table 74. Heptares Therapeutics Ltd Company Information Table 75. Heptares Therapeutics Ltd Business Overview Table 76. Heptares Therapeutics Ltd Orexin Receptor Type 2 Revenue (US$ Million) and Gross Margin (2021-2026) Table 77. Heptares Therapeutics Ltd Orexin Receptor Type 2 Product Portfolio Table 78. Heptares Therapeutics Ltd Recent Development Table 79. Evotec AG Company Information Table 80. Evotec AG Business Overview Table 81. Evotec AG Orexin Receptor Type 2 Revenue (US$ Million) and Gross Margin (2021-2026) Table 82. Evotec AG Orexin Receptor Type 2 Product Portfolio Table 83. Evotec AG Recent Development Table 84. Actelion Pharmaceuticals Ltd Company Information Table 85. Actelion Pharmaceuticals Ltd Business Overview Table 86. Actelion Pharmaceuticals Ltd Orexin Receptor Type 2 Revenue (US$ Million) and Gross Margin (2021-2026) Table 87. Actelion Pharmaceuticals Ltd Orexin Receptor Type 2 Product Portfolio Table 88. Actelion Pharmaceuticals Ltd Recent Development Table 89. Research Programs/Design for This Report Table 90. Authors List of This Report Table 91. Secondary Sources Table 92. Primary Sources List of Figures Figure 1. Orexin Receptor Type 2 Product Image Figure 2. Global Orexin Receptor Type 2 Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Orexin Receptor Type 2 Market Size (2021-2032) & (US$ Million) Figure 4. Global Orexin Receptor Type 2 Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. HTL-6641 Image Figure 8. MK-8133 Image Figure 9. OPN-021 Image Figure 10. YNT-185 Image Figure 11. Lemborexant Image Figure 12. Others Image Figure 13. Global Orexin Receptor Type 2 Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 14. Global Orexin Receptor Type 2 Sales Value Share 2021 VS 2025 VS 2032 Figure 15. Global Orexin Receptor Type 2 Sales Value Share by Type (2021-2032) Figure 16. Major Depressive Disorder Image Figure 17. Sleep Disorders Image Figure 18. Narcolepsy Image Figure 19. Insomnia Image Figure 20. Global Orexin Receptor Type 2 Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 21. Global Orexin Receptor Type 2 Sales Value Share 2021 VS 2025 VS 2032 Figure 22. Global Orexin Receptor Type 2 Sales Value Share by Application (2021-2032) Figure 23. Global Orexin Receptor Type 2 Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 24. Global Orexin Receptor Type 2 Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 25. North America Orexin Receptor Type 2 Sales Value (2021-2032) & (US$ Million) Figure 26. North America Orexin Receptor Type 2 Sales Value Share by Country (%), 2025 VS 2032 Figure 27. Europe Orexin Receptor Type 2 Sales Value (2021-2032) & (US$ Million) Figure 28. Europe Orexin Receptor Type 2 Sales Value Share by Country (%), 2025 VS 2032 Figure 29. Asia-Pacific Orexin Receptor Type 2 Sales Value (2021-2032) & (US$ Million) Figure 30. Asia-Pacific Orexin Receptor Type 2 Sales Value Share by Country (%), 2025 VS 2032 Figure 31. South America Orexin Receptor Type 2 Sales Value (2021-2032) & (US$ Million) Figure 32. South America Orexin Receptor Type 2 Sales Value Share by Country (%), 2025 VS 2032 Figure 33. Middle East & Africa Orexin Receptor Type 2 Sales Value (2021-2032) & (US$ Million) Figure 34. Middle East & Africa Orexin Receptor Type 2 Sales Value Share by Country (%), 2025 VS 2032 Figure 35. USA Orexin Receptor Type 2 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 36. USA Orexin Receptor Type 2 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 37. USA Orexin Receptor Type 2 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 38. Canada Orexin Receptor Type 2 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 39. Canada Orexin Receptor Type 2 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 40. Canada Orexin Receptor Type 2 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 41. Mexico Orexin Receptor Type 2 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 42. Mexico Orexin Receptor Type 2 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 43. Mexico Orexin Receptor Type 2 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 44. Germany Orexin Receptor Type 2 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 45. Germany Orexin Receptor Type 2 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 46. Germany Orexin Receptor Type 2 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 47. France Orexin Receptor Type 2 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 48. France Orexin Receptor Type 2 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 49. France Orexin Receptor Type 2 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 50. U.K. Orexin Receptor Type 2 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 51. U.K. Orexin Receptor Type 2 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 52. U.K. Orexin Receptor Type 2 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 53. Italy Orexin Receptor Type 2 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 54. Italy Orexin Receptor Type 2 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 55. Italy Orexin Receptor Type 2 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 56. Spain Orexin Receptor Type 2 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 57. Spain Orexin Receptor Type 2 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 58. Spain Orexin Receptor Type 2 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 59. Russia Orexin Receptor Type 2 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 60. Russia Orexin Receptor Type 2 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 61. Russia Orexin Receptor Type 2 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 62. Netherlands Orexin Receptor Type 2 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 63. Netherlands Orexin Receptor Type 2 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 64. Netherlands Orexin Receptor Type 2 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 65. Nordic Countries Orexin Receptor Type 2 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 66. Nordic Countries Orexin Receptor Type 2 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 67. Nordic Countries Orexin Receptor Type 2 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 68. China Orexin Receptor Type 2 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 69. China Orexin Receptor Type 2 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 70. China Orexin Receptor Type 2 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 71. Japan Orexin Receptor Type 2 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 72. Japan Orexin Receptor Type 2 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 73. Japan Orexin Receptor Type 2 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 74. South Korea Orexin Receptor Type 2 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 75. South Korea Orexin Receptor Type 2 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 76. South Korea Orexin Receptor Type 2 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 77. India Orexin Receptor Type 2 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 78. India Orexin Receptor Type 2 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 79. India Orexin Receptor Type 2 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 80. Australia Orexin Receptor Type 2 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 81. Australia Orexin Receptor Type 2 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 82. Australia Orexin Receptor Type 2 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 83. Southeast Asia Orexin Receptor Type 2 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 84. Southeast Asia Orexin Receptor Type 2 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 85. Southeast Asia Orexin Receptor Type 2 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 86. Brazil Orexin Receptor Type 2 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 87. Brazil Orexin Receptor Type 2 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 88. Brazil Orexin Receptor Type 2 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 89. Argentina Orexin Receptor Type 2 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 90. Argentina Orexin Receptor Type 2 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 91. Argentina Orexin Receptor Type 2 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 92. Chile Orexin Receptor Type 2 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 93. Chile Orexin Receptor Type 2 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 94. Chile Orexin Receptor Type 2 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 95. Colombia Orexin Receptor Type 2 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 96. Colombia Orexin Receptor Type 2 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 97. Colombia Orexin Receptor Type 2 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 98. Peru Orexin Receptor Type 2 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 99. Peru Orexin Receptor Type 2 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 100. Peru Orexin Receptor Type 2 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 101. Saudi Arabia Orexin Receptor Type 2 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 102. Saudi Arabia Orexin Receptor Type 2 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 103. Saudi Arabia Orexin Receptor Type 2 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 104. Israel Orexin Receptor Type 2 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 105. Israel Orexin Receptor Type 2 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 106. Israel Orexin Receptor Type 2 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 107. UAE Orexin Receptor Type 2 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 108. UAE Orexin Receptor Type 2 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 109. UAE Orexin Receptor Type 2 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 110. Turkey Orexin Receptor Type 2 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 111. Turkey Orexin Receptor Type 2 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 112. Turkey Orexin Receptor Type 2 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 113. Iran Orexin Receptor Type 2 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 114. Iran Orexin Receptor Type 2 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 115. Iran Orexin Receptor Type 2 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 116. Egypt Orexin Receptor Type 2 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 117. Egypt Orexin Receptor Type 2 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 118. Egypt Orexin Receptor Type 2 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 119. Years Considered Figure 120. Research Process Figure 121. Key Executives Interviewed

Scope & coverage.

Types
  • HTL-6641
  • MK-8133
  • OPN-021
  • YNT-185
  • Lemborexant
  • Others
Applications
  • Major Depressive Disorder
  • Sleep Disorders
  • Narcolepsy
  • Insomnia
Companies covered
  • Yangtze River Pharmaceutical Group
  • Eisai Co Ltd
  • Johnson & Johnson
  • Merck & Co Inc
  • OptiNose US Inc
  • Idorsia Ltd
  • Heptares Therapeutics Ltd
  • Evotec AG
  • Actelion Pharmaceuticals Ltd

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Orexin Receptor Type 2 Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Orexin Receptor Type 2 Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Orexin Receptor Type 2 Market Dynamics
  1. 2.1 Orexin Receptor Type 2 Industry Trends
  2. 2.2 Orexin Receptor Type 2 Industry Drivers
  3. 2.3 Orexin Receptor Type 2 Industry Opportunities and Challenges
  4. 2.4 Orexin Receptor Type 2 Industry Restraints
3 Orexin Receptor Type 2 Market by Company
  1. 3.1 Global Orexin Receptor Type 2 Company Revenue Ranking in 2025
  2. 3.2 Global Orexin Receptor Type 2 Revenue by Company (2021-2026)
  3. 3.3 Global Orexin Receptor Type 2 Company Ranking (2024-2026)
  4. 3.4 Global Orexin Receptor Type 2 Company Manufacturing Base and Headquarters
  5. 3.5 Global Orexin Receptor Type 2 Company Product Type and Application
  6. 3.6 Global Orexin Receptor Type 2 Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Orexin Receptor Type 2 Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Orexin Receptor Type 2 Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Orexin Receptor Type 2 Market by Type
  1. 4.1 Orexin Receptor Type 2 Type Introduction
  2. 4.1.1 HTL-6641
  3. 4.1.2 MK-8133
  4. 4.1.3 OPN-021
  5. 4.1.4 YNT-185
  6. 4.1.5 Lemborexant
  7. 4.1.6 Others
  8. 4.2 Global Orexin Receptor Type 2 Sales Value by Type
  9. 4.2.1 Global Orexin Receptor Type 2 Sales Value by Type (2021 VS 2025 VS 2032)
  10. 4.2.2 Global Orexin Receptor Type 2 Sales Value by Type (2021-2032)
  11. 4.2.3 Global Orexin Receptor Type 2 Sales Value Share by Type (2021-2032)
5 Orexin Receptor Type 2 Market by Application
  1. 5.1 Orexin Receptor Type 2 Application Introduction
  2. 5.1.1 Major Depressive Disorder
  3. 5.1.2 Sleep Disorders
  4. 5.1.3 Narcolepsy
  5. 5.1.4 Insomnia
  6. 5.2 Global Orexin Receptor Type 2 Sales Value by Application
  7. 5.2.1 Global Orexin Receptor Type 2 Sales Value by Application (2021 VS 2025 VS 2032)
  8. 5.2.2 Global Orexin Receptor Type 2 Sales Value by Application (2021-2032)
  9. 5.2.3 Global Orexin Receptor Type 2 Sales Value Share by Application (2021-2032)
6 Orexin Receptor Type 2 Regional Value Analysis
  1. 6.1 Global Orexin Receptor Type 2 Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Orexin Receptor Type 2 Sales Value by Region (2021-2032)
  3. 6.2.1 Global Orexin Receptor Type 2 Sales Value by Region: 2021-2026
  4. 6.2.2 Global Orexin Receptor Type 2 Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Orexin Receptor Type 2 Sales Value (2021-2032)
  7. 6.3.2 North America Orexin Receptor Type 2 Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Orexin Receptor Type 2 Sales Value (2021-2032)
  10. 6.4.2 Europe Orexin Receptor Type 2 Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Orexin Receptor Type 2 Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Orexin Receptor Type 2 Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Orexin Receptor Type 2 Sales Value (2021-2032)
  16. 6.6.2 South America Orexin Receptor Type 2 Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Orexin Receptor Type 2 Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Orexin Receptor Type 2 Sales Value Share by Country, 2025 VS 2032
7 Orexin Receptor Type 2 Country-level Value Analysis
  1. 7.1 Global Orexin Receptor Type 2 Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Orexin Receptor Type 2 Sales Value by Country (2021-2032)
  3. 7.2.1 Global Orexin Receptor Type 2 Sales Value by Country (2021-2026)
  4. 7.2.2 Global Orexin Receptor Type 2 Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Orexin Receptor Type 2 Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Orexin Receptor Type 2 Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Orexin Receptor Type 2 Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Orexin Receptor Type 2 Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Orexin Receptor Type 2 Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Orexin Receptor Type 2 Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Orexin Receptor Type 2 Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Orexin Receptor Type 2 Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Orexin Receptor Type 2 Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Orexin Receptor Type 2 Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Orexin Receptor Type 2 Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Orexin Receptor Type 2 Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Orexin Receptor Type 2 Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Orexin Receptor Type 2 Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Orexin Receptor Type 2 Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Orexin Receptor Type 2 Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Orexin Receptor Type 2 Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Orexin Receptor Type 2 Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Orexin Receptor Type 2 Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Orexin Receptor Type 2 Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Orexin Receptor Type 2 Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Orexin Receptor Type 2 Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Orexin Receptor Type 2 Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Orexin Receptor Type 2 Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Orexin Receptor Type 2 Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Orexin Receptor Type 2 Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Orexin Receptor Type 2 Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Orexin Receptor Type 2 Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Orexin Receptor Type 2 Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Orexin Receptor Type 2 Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Orexin Receptor Type 2 Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Orexin Receptor Type 2 Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Orexin Receptor Type 2 Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Orexin Receptor Type 2 Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Orexin Receptor Type 2 Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Orexin Receptor Type 2 Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Orexin Receptor Type 2 Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Orexin Receptor Type 2 Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Orexin Receptor Type 2 Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Orexin Receptor Type 2 Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Orexin Receptor Type 2 Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Orexin Receptor Type 2 Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Orexin Receptor Type 2 Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Orexin Receptor Type 2 Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Orexin Receptor Type 2 Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Orexin Receptor Type 2 Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Orexin Receptor Type 2 Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Orexin Receptor Type 2 Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Orexin Receptor Type 2 Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Orexin Receptor Type 2 Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Orexin Receptor Type 2 Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Orexin Receptor Type 2 Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Orexin Receptor Type 2 Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Orexin Receptor Type 2 Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Orexin Receptor Type 2 Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Orexin Receptor Type 2 Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Orexin Receptor Type 2 Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Orexin Receptor Type 2 Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Orexin Receptor Type 2 Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Orexin Receptor Type 2 Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Orexin Receptor Type 2 Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Orexin Receptor Type 2 Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Orexin Receptor Type 2 Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Orexin Receptor Type 2 Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Orexin Receptor Type 2 Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Orexin Receptor Type 2 Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Orexin Receptor Type 2 Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Orexin Receptor Type 2 Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Orexin Receptor Type 2 Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Orexin Receptor Type 2 Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Orexin Receptor Type 2 Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Orexin Receptor Type 2 Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Orexin Receptor Type 2 Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Orexin Receptor Type 2 Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Orexin Receptor Type 2 Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Orexin Receptor Type 2 Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Orexin Receptor Type 2 Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Orexin Receptor Type 2 Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Orexin Receptor Type 2 Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Orexin Receptor Type 2 Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Orexin Receptor Type 2 Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Orexin Receptor Type 2 Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Orexin Receptor Type 2 Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Orexin Receptor Type 2 Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Yangtze River Pharmaceutical Group
  2. 8.1.1 Yangtze River Pharmaceutical Group Company Information
  3. 8.1.2 Yangtze River Pharmaceutical Group Business Overview
  4. 8.1.3 Yangtze River Pharmaceutical Group Orexin Receptor Type 2 Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Yangtze River Pharmaceutical Group Orexin Receptor Type 2 Product Portfolio
  6. 8.1.5 Yangtze River Pharmaceutical Group Recent Developments
  7. 8.2 Eisai Co Ltd
  8. 8.2.1 Eisai Co Ltd Company Information
  9. 8.2.2 Eisai Co Ltd Business Overview
  10. 8.2.3 Eisai Co Ltd Orexin Receptor Type 2 Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Eisai Co Ltd Orexin Receptor Type 2 Product Portfolio
  12. 8.2.5 Eisai Co Ltd Recent Developments
  13. 8.3 Johnson & Johnson
  14. 8.3.1 Johnson & Johnson Company Information
  15. 8.3.2 Johnson & Johnson Business Overview
  16. 8.3.3 Johnson & Johnson Orexin Receptor Type 2 Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Johnson & Johnson Orexin Receptor Type 2 Product Portfolio
  18. 8.3.5 Johnson & Johnson Recent Developments
  19. 8.4 Merck & Co Inc
  20. 8.4.1 Merck & Co Inc Company Information
  21. 8.4.2 Merck & Co Inc Business Overview
  22. 8.4.3 Merck & Co Inc Orexin Receptor Type 2 Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Merck & Co Inc Orexin Receptor Type 2 Product Portfolio
  24. 8.4.5 Merck & Co Inc Recent Developments
  25. 8.5 OptiNose US Inc
  26. 8.5.1 OptiNose US Inc Company Information
  27. 8.5.2 OptiNose US Inc Business Overview
  28. 8.5.3 OptiNose US Inc Orexin Receptor Type 2 Revenue and Gross Margin (2021-2026)
  29. 8.5.4 OptiNose US Inc Orexin Receptor Type 2 Product Portfolio
  30. 8.5.5 OptiNose US Inc Recent Developments
  31. 8.6 Idorsia Ltd
  32. 8.6.1 Idorsia Ltd Company Information
  33. 8.6.2 Idorsia Ltd Business Overview
  34. 8.6.3 Idorsia Ltd Orexin Receptor Type 2 Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Idorsia Ltd Orexin Receptor Type 2 Product Portfolio
  36. 8.6.5 Idorsia Ltd Recent Developments
  37. 8.7 Heptares Therapeutics Ltd
  38. 8.7.1 Heptares Therapeutics Ltd Company Information
  39. 8.7.2 Heptares Therapeutics Ltd Business Overview
  40. 8.7.3 Heptares Therapeutics Ltd Orexin Receptor Type 2 Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Heptares Therapeutics Ltd Orexin Receptor Type 2 Product Portfolio
  42. 8.7.5 Heptares Therapeutics Ltd Recent Developments
  43. 8.8 Evotec AG
  44. 8.8.1 Evotec AG Company Information
  45. 8.8.2 Evotec AG Business Overview
  46. 8.8.3 Evotec AG Orexin Receptor Type 2 Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Evotec AG Orexin Receptor Type 2 Product Portfolio
  48. 8.8.5 Evotec AG Recent Developments
  49. 8.9 Actelion Pharmaceuticals Ltd
  50. 8.9.1 Actelion Pharmaceuticals Ltd Company Information
  51. 8.9.2 Actelion Pharmaceuticals Ltd Business Overview
  52. 8.9.3 Actelion Pharmaceuticals Ltd Orexin Receptor Type 2 Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Actelion Pharmaceuticals Ltd Orexin Receptor Type 2 Product Portfolio
  54. 8.9.5 Actelion Pharmaceuticals Ltd Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst